The Ministry of Health and Prevention in the United Arab Emirates has granted marketing authorization for oral, once-daily Orladeyo (berotralstat) for the prevention of recurrent attacks in patients with HAE 12 years and older. To support commercialization efforts in the United Arab Emirates, BioCryst Pharmaceuticals, Inc. has entered into a supply and distribution agreement with NewBridge Pharmaceuticals, which also covers the Gulf Cooperation Council and Iraq.
“As the first targeted oral, once-daily treatment, Orladeyo provides an important new treatment option for patients and physicians,” said Henrik Balle Boysen, Executive Vice President and COO of HAEi. “While there is still more work to be done to raise awareness to support earlier diagnosis and treatment, the approval of Orladeyo is an important advancement for HAE patients in the United Arab Emirates.”
“With many prevalent rare diseases in the Middle East and North Africa region, I am personally inspired, and we at NewBridge are proud, to be part of this partnership with BioCryst for the United Arab Emirates and a number of other markets in the Gulf Cooperation Council. This partnership supports our mission by providing access to an important new therapy for HAE patients in a hope that we can help ease their suffering and support them to live better lives,” says Joe Henein, President and CEO of NewBridge Pharma.
“NewBridge is the right partner for BioCryst as they share our vision to bring innovative medicines to patients living with rare diseases,” says Charlie Gayer, CCO of BioCryst. “With experience across regulatory, medical and commercial, and strong local relationships with key stakeholders, NewBridge will help accelerate our efforts to bring Orladeyo to patients across the globe by providing a much-needed new option to HAE patients in the United Arab Emirates.”
NewBridge Pharmaceuticals, headquartered in Dubai, the United Arab Emirates, is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize U.S. Food and Drug Administration or European Medicines Agency approved innovative therapeutics that address unmet medical needs into the Middle East and North Africa regions.